Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -36.79% | 10,564.71% | |||
| Gross Profit | 36.79% | -10,564.71% | |||
| SG&A Expenses | -22.25% | 6.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.19% | 41.60% | |||
| Operating Income | 27.19% | -41.60% | |||
| Income Before Tax | 26.38% | -149.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.38% | -149.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.38% | -149.56% | |||
| EBIT | 27.19% | -41.60% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 26.67% | -150.00% | |||
| Normalized Basic EPS | 26.32% | -137.50% | |||
| EPS Diluted | 26.67% | -150.00% | |||
| Normalized Diluted EPS | 26.32% | -137.50% | |||
| Average Basic Shares Outstanding | 0.62% | 1.42% | |||
| Average Diluted Shares Outstanding | 0.62% | 1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||